Download PDF
Seminars in Neurosurgery 2003; 14(3): 279-286
DOI: 10.1055/s-2004-828932
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Recurrent Meningiomas

Gail L. Rosseau, Cengiz Cokluk
  • Department of Neurosurgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, and Chicago Institute of Neurosurgery and Neuroresearch, Chicago, Illinois
Further Information

Publication History

Publication Date:
02 June 2004 (online)

    Permissions and Reprints

ABSTRACT

With innovations in microneurosurgical techniques and equipment in the recent era, many difficult meningiomas can be removed completely in the hands of experienced neurosurgeons. Specific cranial base approaches provide a dissection technique focused on bone removal, rather than brain retraction, which is critical to the safe resection of deeply seated meningiomas. The surgical aim has focused not only on patients' survival but also on quality of life. Despite these advances, challenges remain in the treatment of meningiomas. Notable among these is the tendency of meningiomas to recur. Factors affecting the recurrence rate are age, sex, histology, location, and the modality of surgical treatment. Recurrence rates for benign meningiomas range from 4 to 52%. Volume of tumor removed and tumor attachment to neighboring tissues affect the recurrence rate. Magnetic resonance imaging is the most useful diagnostic tool in the detection of postoperative residual and recurrent tumor. Surgery remains the first option in the treatment of most recurrent meningiomas. Adjunctive treatments may be considered in selected cases.

KEYWORDS

Difficult meningiomas - recurrent meningiomas

REFERENCES

  • 1 Bingham W F. W.W. Keen and the dawn of American neurosurgery.  J Neurosurg . 1986;  64 705-712
    PubMedGoogle Scholar
  • 2 Cushing H W, Eisenhardt L. Meningiomas: Their Classification, Regional Behavior, Life History, and Surgical End Results.  Springfield, IL: Charles C Thomas 1938: 47-71
    Google Scholar
  • 3 Simpson D. The recurrence of intracranial meningiomas after surgical treatment.  J Neurol Neurosurg Psychiatry . 1957;  20 22-39
    CrossrefPubMedGoogle Scholar
  • 4 Mathiesen T, Von Holst H, Askensten U, Collins P. DNA determination in the clinical management of patients with meningioma or hemangioblastoma.  Br J Neurosurg . 1989;  3 575-581
    PubMedGoogle Scholar
  • 5 Mirimanoff R O, Dosoretz D E, Linggood R M, Ojemann R G, Martuza R L. Meningioma: analysis of recurrence and progression following neurosurgical resection.  J Neurosurg . 1985;  62 18-24
    CrossrefPubMedGoogle Scholar
  • 6 Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis.  Surg Neurol . 1986;  26 461-469
    PubMedGoogle Scholar
  • 7 Adegbite A B, Khan M I, Paine K W, Tan L K. The recurrence of intracranial meningiomas after surgical treatment.  J Neurosurg . 1983;  58 51-56
    CrossrefPubMedGoogle Scholar
  • 8 Beks J W, de Windt L H. The recurrence of supratentorial meningiomas after surgery.  Acta Neurochir (Wien) . 1988;  95 3-5
    CrossrefPubMedGoogle Scholar
  • 9 Chan R C, Thompson G B. Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases.  J Neurosurg . 1984;  60 52-60
    CrossrefPubMedGoogle Scholar
  • 10 Giombini S, Solero C L, Morello G. Late outcome of operations for supratentorial convexity meningiomas. Report on 207 cases.  Surg Neurol . 1984;  22 588-594
    PubMedGoogle Scholar
  • 11 Philippon J, Cornu P. The recurrence of meningiomas. In: Al-Mefty O, ed. Meningiomas New York: Raven Press 1991: 87-105
    Google Scholar
  • 12 Skullerud K, Loken A C. The prognosis in meningiomas.  Acta Neuropathol (Berl) . 1974;  29 337-344
    CrossrefPubMedGoogle Scholar
  • 13 Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas.  Cancer . 2000;  89 1102-1110
    CrossrefPubMedGoogle Scholar
  • 14 Alvarez F, Roda J M, Perez Romero M, Morales C, Sarmiento M A, Blazquez M G. Malignant and atypical meningiomas: a reappraisal of clinical, histological, and computed tomographic features.  Neurosurgery . 1987;  20 688-694
    PubMedGoogle Scholar
  • 15 Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome.  Surg Neurol . 1986;  25 233-242
    PubMedGoogle Scholar
  • 16 Maier H, Ofner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance.  J Neurosurg . 1992;  77 616-623
    PubMedGoogle Scholar
  • 17 Palma L, Celli P, Franco C, Cervoni L, Cantore G. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.  J Neurosurg . 1997;  86 793-800
    CrossrefPubMedGoogle Scholar
  • 18 Mathiesen T, Lindquist C, Kihlstrom L, Karlsson B. Recurrence of cranial base meningiomas.  Neurosurgery . 1996;  39 2-7
    CrossrefPubMedGoogle Scholar
  • 19 Zulch K J. Histologic Typing of Tumors of the Central Nervous System.  Geneva: World Health Organization; 1979
    Google Scholar
  • 20 Kepes J J. Review of the WHO's new proposed classification of brain tumors. Proceedings of the XIth International Congress of Neuropathology, Kyoto, Japan, 1990, pp 87-97
    Google Scholar
  • 21 Kleihues P, Cavenee W K. Pathology and genetics of tumors of the nervous system (WHO). Lyon: International Agency for Research on Cancer (IARCH Press) 2000
    Google Scholar
  • 22 Von Deimling A, Larson J, Wellenreuther R. et al . Clonal origin of recurrent meningiomas.  Brain Pathol . 1999;  9 645-650
    PubMedGoogle Scholar
  • 23 Wilson C B. Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider Lecture.  J Neurosurg . 1994;  81 666-675
    PubMedGoogle Scholar
  • 24 Kunishio K, Ohmoto T, Matsuhisa T, Maeshiro T, Furuta T, Matsumoto K. The significance of nuclear organizer region (AgNOR) score in predicting meningioma recurrence.  Cancer . 1994;  73 2200-2205
    PubMedGoogle Scholar
  • 25 Moller M L, Braendstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry.  J Neurooncol . 1997;  34 241-246
    CrossrefPubMedGoogle Scholar
  • 26 Takeuchi H, Kubota T, Kabuto M, Kitai R, Nozaki J, Yamashita J. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study.  Surg Neurol . 1997;  48 501-506
    CrossrefPubMedGoogle Scholar
  • 27 Cobb M A, Husain M, Andersen B J, Al-Mefty O. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.  J Neurosurg . 1996;  84 85-90
    PubMedGoogle Scholar
  • 28 De Ridder L. Meningiomas: behavior in vivo and in vitro. In: Mikkelson T, Bjerkving R, Laerum OD, Rosenblum ML, eds. Brain Tumor Invasion: Biological, Clinical and Therapeutic Consideration New York: John Wiley & Sons; 1998
    Google Scholar
  • 29 Kakinuma K, Tanaka R, Onda K, Takahashi H. Proliferative potential of recurrent intracranial meningiomas as evaluated by labeling indices of BUdR and Ki-67, and tumor doubling time.  Acta Neurochir (Wien) . 1998;  140 26-31
    CrossrefPubMedGoogle Scholar
  • 30 Matsuno A, Fujimaki T, Sasaki T. et al . Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.  Acta Neuropathol (Berl) . 1996;  91 504-510
    CrossrefPubMedGoogle Scholar
  • 31 Shibuya M, Hoshino T, Ito S. et al . Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.  Neurosurgery . 1992;  30 494-497
    PubMedGoogle Scholar
  • 32 Zankl H, Zang K D. Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique.  Humangenetik . 1972;  14 167-169
    CrossrefPubMedGoogle Scholar
  • 33 Weber R G, Bostrom J, Wolter M. et al . Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression.  Proc Natl Acad Sci U S A . 1997;  94 14719-14724
    CrossrefPubMedGoogle Scholar
  • 34 Prayson R A. Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry.  Am J Clin Pathol . 1996;  105 719-726
    PubMedGoogle Scholar
  • 35 Nakabayashi H, Shimizu K, Hara M. Prognostic significance of cyclin A expression in meningiomas.  Appl Immunohistochem Mol Morphol . 2003;  11 9-14
    CrossrefPubMedGoogle Scholar
  • 36 Konstantinidou A E, Korkolopoulou P, Kavantzas N. et al . Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas.  Histol Histopathol . 2003;  18 67-74
    PubMedGoogle Scholar
  • 37 Kilic T, Bayri Y, Ozduman K. et al . Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape.  Neurosurgery . 2002;  51 183-192
    CrossrefPubMedGoogle Scholar
  • 38 Levicar N, Strojnik T, Kos J, Dewey R A, Pilkington G J, Lah T T. Lysosomal enzymes. Cathepsins in brain tumor invasion.  J Neurooncol . 2002;  58 21-32
    CrossrefPubMedGoogle Scholar
  • 39 Strojnik T, Zidanik B, Kos J, Lah T T. Cathepsins B and L are markers for clinically invasive types of meningiomas.  Neurosurgery . 2001;  48 598-605
    CrossrefPubMedGoogle Scholar
  • 40 Simon M, Park T W, Leuenroth S, Hans V H, Loning T, Schramm J. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.  J Neurosurg . 2000;  92 832-840
    PubMedGoogle Scholar
  • 41 Hunt D P, Freeman A, Morris L S. et al . Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein.  Br J Neurosurg . 2002;  16 10-15
    CrossrefPubMedGoogle Scholar
  • 42 Konstantinidou A E, Patsouris E, Korkolopoulou P, Kavantzas N, Mahera H, Davaris P. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.  Histopathology . 2001;  39 402-408
    CrossrefPubMedGoogle Scholar
  • 43 Bonnal J, Brotchi J. Surgery of the superior sagittal sinus in parasagittal meningiomas.  J Neurosurg . 1978;  48 935-945
    PubMedGoogle Scholar
  • 44 Barbaro N M, Gutin P H, Wilson C B, Sheline G E, Boldrey E B, Wara W M. Radiation therapy in the treatment of partially resected meningiomas.  Neurosurgery . 1987;  20 525-528
    PubMedGoogle Scholar
  • 45 Kokubo M, Shibamoto Y, Takahashi J A. et al . Efficacy of conventional radiotherapy for recurrent meningioma.  J Neurooncol . 2000;  48 51-55
    CrossrefPubMedGoogle Scholar
  • 46 Mesic J B, Hanks G E, Doggett R L. The value of radiation therapy as an adjuvant to surgery in intracranial meningiomas.  Am J Clin Oncol . 1986;  9 337-340
    PubMedGoogle Scholar
  • 47 Solan M J, Kramer S. The role of radiation therapy in the management of intracranial meningiomas.  Int J Radiat Oncol Biol Phys . 1985;  11 675-677
    PubMedGoogle Scholar
  • 48 Taylor Jr W B, Marcus Jr B R, Friedman W A, Ballinger Jr E W, Million R R. The meningioma controversy: postoperative radiation therapy.  Int J Radiat Oncol Biol Phys . 1988;  15 299-304
    PubMedGoogle Scholar
  • 49 Wara W M, Sheline G E, Newman H, Townsend J J, Boldrey E B. Radiation therapy of meningiomas.  Am J Roentgenol Radium Ther Nucl Med . 1975;  123 453-458
    CrossrefPubMedGoogle Scholar
  • 50 Wenkel E, Thornton A F, Finkelstein D. et al . Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy.  Int J Radiat Oncol Biol Phys . 2000;  l48 1363-1370
    PubMedGoogle Scholar
  • 51 Debus J, Wuendrich M, Pirzkall A. et al . High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results.  J Clin Oncol . 2001;  19 3547-3553
    PubMedGoogle Scholar
  • 52 Kondziolka D, Lunsford L D, Coffey R J, Flickinger J C. Stereotactic radiosurgery of meningiomas.  J Neurosurg . 1991;  74 552-559
    CrossrefPubMedGoogle Scholar
  • 53 Kobayashi T, Kida Y, Mori Y. Long-term results of stereotactic gamma radiosurgery of meningiomas.  Surg Neurol . 2001;  55 325-331
    CrossrefPubMedGoogle Scholar
  • 54 Gutin P H, Leibel S A, Hosobuchi Y. et al . Brachytherapy of recurrent tumors of the skull base and spine with iodine-125 sources.  Neurosurgery . 1987;  20 938-945
    PubMedGoogle Scholar
  • 55 Kumar P P, Patil A A, Syh H W, Chu W K, Reeves M A. Role of brachytherapy in the management of the skull base meningioma. Treatment of skull base meningiomas.  Cancer . 1993;  71 3726-3731
    CrossrefPubMedGoogle Scholar
  • 56 Kyritsis A P. Chemotherapy for meningiomas.  J Neurooncol . 1996;  29 269-272
    CrossrefPubMedGoogle Scholar
  • 57 Kaba S E, DeMonte F, Bruner J M. et al . The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.  Neurosurgery . 1997;  40 271-275
    CrossrefPubMedGoogle Scholar
  • 58 Schrell U M, Rittig M G, Anders M. et al . Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.  J Neurosurg . 1997;  86 840-844
    CrossrefPubMedGoogle Scholar
  • 59 Schrell U M, Rittig M G, Anders M. et al . Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.  J Neurosurg . 1997;  86 845-852
    CrossrefPubMedGoogle Scholar
  • 60 Koper J W, Zwarthoff E C, Hagemeijer A. et al . Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.  Eur J Cancer . 1991;  27 416-419
    PubMedGoogle Scholar